Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Neovasc Inc (NVCN) announced that the U.S. District Court in Massachusetts has granted its motion to dismiss the class action lawsuit Grobler v. Neovasc, et al. (Civil Action No. 16-11038-RGS). The court ruled in favor of the company and its officers on all claims and ordered the case closed. The stock closed at $0.520, up 7.11% in the Wednesday trading session. It touched intraday high of $0.61
Neovasc was sued by various law firms following the loss of a patent case against Edwards Lifesciences (EW) unit CardiAQ earlier this year.

Eli Lilly and Company (LLY) stock plunged more than 10% in the Wednesday trading session. It touched intraday low of $64.18 before closing at $68.00. The stock tanked on the news of its experimental drug failing to slow the loss of cognitive ability in patients with mild Alzheimer's disease. The company had tested more than 2,100 patients for its Phase III Clinical trials study.
Eli Lilly said that it won't seek U.S. approval of solanezumab, the infused drug for mild dementia. The company’s outgoing CEO said that the company has pipeline of potential treatments for Alzheimer. He added, “We have an oral drug we're testing now in Phase III. We have five other therapeutic agents in early stages of development.”

• The Senate Judiciary Committee announced that it has postponed its hearing on EpiPen pricing. The committee said that it is considering “other avenues to ensure government and company witnesses participate." The hearing was scheduled for November 30.

• The FDA granted 501(K) clearance to Xtant Medical Holdings (NYSEMKT:XTNT) Xsert Lumbar Expandable Interbody System. It is an all-titanium adjustable height device used in spinal fusion surgery and can be inserted in a tighter corridor then expanded as per the patient's anatomy.

• Navidea Biopharmaceuticals (NAVB) is reported to have inked an asset purchase agreement with Cardinal Health (CAH). Under the terms of the deal, Navidea will receive $80M at the closing of the deal. It will also receive $230M in milestones through 2026, with $20.1M guaranteed over the next three years. The deal is expected to close in the first quarter of the next year.
• Prima Biomed (PBMD) and WuXi AppTec's WuXi Biologics signed a Memorandum of Understanding (MOU) for forming a strategic partnership to develop and manufacture biologics. WuXi will be Prima's preferred partner to manufacture potential new products.

• Ablynx NV (ABLYF) announced quarterly earnings at Euro 10.9 per share. Its revenue stood at Euro 68.9 million.

• Credit Suisse downgrades Diplomat Pharmacy (DPLO) due to "slowing organic growth and profit challenges” New rating Underperform, New price target $13.
• Mizuho Securities downgrades Valeant Pharmaceuticals (VRX), New rating Underperform, Price target $11.

• Arbiter Partners Capital Management LLC, a 10% holder of Capital Senior Living Corp, purchased 20,169 shares at $15.60 per share.

None to report.

Gainers Change Mkt Cap
Moog Inc 37.17% 2.58B
Caleres Inc 14.20% 1.45B
Veeva Systems 11.38% 7.02B
Deere & Company 11.04% 32.02B
Seadrill Ltd 10.04% 1.44B

Losers Change Mkt Cap
Juno Therapeutics Inc -24.50% 2.27B
Direxion Shares Ex. -14.86% 1.44B
Urban Outfitters, Inc. -12.05% 3.71B
Eli Lilly and Co -10.51% 74.43B
Coeur Mining Inc -8.50% 1.67B